Igen
This article was originally published in The Gray Sheet
Executive Summary
Private equity financing raises $9.5 mil. for R&D and working capital. The sale of 789,075 shares to Acqua Wellington North American Equities Fund was made under a February financing agreement covering the sale of up to $60 mil. of Igen's common stock over 28 months. Separately, a pretrial hearing in the biological detection system firm's 1997 breach of contract suit against Roche Diagnostics relating to a 1992 licensing agreement has dismissed Roche's counterclaim for fraud and struck down Roche's request for punitive damages. The U.S. District Court in Maryland has set a trial date of Oct. 23 (1"The Gray Sheet" April 10, 2000, p. 22)
You may also be interested in...
Roche Sees Minimal Elecsys Financial Impact In Wake Of IGEN Court Order
Roche Diagnostics expects only a "small percentage" of its Elecsys line of immunoassay analyzers incorporating IGEN's Origen technology will be affected by an upcoming court-ordered transfer of Elecsys physician office laboratory accounts to IGEN.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.